



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------------|------------------------|---------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/501,318-Conf. #6122 | | |
| | | Filing Date | February 25, 2005 | | |
| | | First Named Inventor | Laurence Gamelin | | |
| | | Art Unit | 1632 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | REGIM 3.3-026 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Country Code ² -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| /J.K./ | BA | WO-01/74368-A1 | 10-11-2001 | Angiogene Pharmaceuticals | | ✓ |
| /J.K./ | BB | WO-01/08693-A2 | 02-08-2001 | Tularik | | ✓ |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ³ |
| /J.K./ | CA | GROLLEAU et al., "A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels", Journal of Neurophysiology, Vol 85, No. 5, pgs 2293-2297, 2001 | | | |
| /J.K./ | CB | BERTHEAULT-CVITKOVIC et al., "Biweekly Intensified Ambulatory Chronomodulated Chemotherapy With Oxaliplatin, Fluororacil, and Leucovorin in Patients With Metastatic Colorectal Cancer", J. Clin. Oncol., Vol. 14, No. 11, pgs. 2950-2958, 1996 | | | |
| /J.K./ | CC | MACHOVER et al., "Two Consecutive phase II studies of oxaliplatin (I-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines", Annals of Oncology, Vol. 7, pgs 95-98, 1996 | | | |
| /J.K./ | CD | MOLLMAN, Cisplatin Neurotoxicity, New England Journal of Medicine, Vol. 322, pgs. 126-127, 1990 | | | |
| /J.K./ | CE | HAGLER et al., "Oxalate metabolism.IV1", The American Journal of Clinical Nutrition, Vol. 26, No. 9, pgs. 1073-1079, September 1973 | | | |
| /J.K./ | CF | RIZZO et al., "Mechanisms of Paresthesiae, Dysesthesiae, and Hyperesthesiae: Role of Na ⁺ Channel Heterogeneity", European Neurology, Vol. 36, pgs 3-12, 1996 | | | |
| /J.K./ | CG | Sweg-Hsien et al., "Indinavir urolithiasis", Current Opinion in Urology, Vol. 10, No. 6, pgs. 557-561, 2000 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

606797.1

| | | | |
|-----------------------|----------------|--------------------|------------|
| Examiner Signature | /Joseph Kudla/ | Date Considered | 08/16/2007 |
|-----------------------|----------------|--------------------|------------|